ストックスクリーナーアプリを入手
119.12
3.08%
-3.78
前日終値:
$122.90
開ける：
$120.01
24時間の取引高:
1.69M
Relative Volume:
1.48
時価総額：
$9.27B
収益：
-
当期純損益:
$-159.39M
株価収益率:
-33.65
EPS:
-3.5401
ネットキャッシュフロー:
$-105.22M
1週間 パフォーマンス:
+7.91%
1か月 パフォーマンス:
+29.94%
6か月 パフォーマンス:
+1,947%
1年 パフォーマンス:
+1,269%
1日の値動き範囲:
$114.06
$122.75
1週間の範囲:
$110.25
$126.99
52週間の値動き範囲:
$4.77
$126.99
Abivax Adr Stock (ABVX) Company Profile
ABVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
119.12 | 9.57B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-06 | 開始されました | Wolfe Research | Outperform |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-07-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | Laidlaw | Buy |
| 2024-05-20 | 開始されました | BTIG Research | Buy |
| 2024-04-29 | 開始されました | Guggenheim | Buy |
| 2024-04-29 | 開始されました | Piper Sandler | Overweight |
| 2023-11-14 | 開始されました | Leerink Partners | Outperform |
| 2023-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Abivax Adr (ABVX) 最新ニュース
Abivax (NASDAQ:ABVX) Sees Large Volume IncreaseHere's Why - MarketBeat
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025 - ts2.tech
Is Abivax ADR (ABVX) positioned for future growth? - Setenews
Healthy Upside Potential: Soligenix Inc (SNGX) - Setenews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month HighStill a Buy? - MarketBeat
Abivax (NASDAQ:ABVX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? - sharewise.com
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know - sharewise.com
A new trading data show Abivax ADR (ABVX) is showing positive returns. - Setenews
Akebia Therapeutics (AKBA) Receives a Buy from BTIG - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
Get in on Abivax ADR’s (ABVX) buy-in window today! - Setenews
Wall Street analysts’ outlook for Zevia PBC (ZVIA) - Setenews
Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating - TipRanks
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Decrease in Short Interest - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Leerink Partnrs Analysts Raise Earnings Estimates for Abivax - Defense World
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Abivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis Study - MSN
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease - Investor's Business Daily
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewswire Inc.
FY2025 EPS Estimates for Abivax Boosted by Lifesci Capital - Defense World
Abivax SA Reports Financial Results and Strategic Advances - MSN
Abivax Reports Increased Losses but Secures Major Funding in H1 2025 - msn.com
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 42.1% in August - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short Interest - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap Down – What’s Next? - Defense World
Octagon Capital Advisors LP Makes New $7.69 Million Investment in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 38.0% in August - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages - Defense World
Promising Outlook for Abivax SA: Buy Rating Supported by Strong Clinical Results and Financial Position - TipRanks
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season - FinancialContent
Abivax SA Sponsored ADR $ABVX Stock Position Increased by ADAR1 Capital Management LLC - MarketBeat
Paloma Partners Management Co Purchases Shares of 38,449 Abivax SA Sponsored ADR $ABVX - MarketBeat
Nantahala Capital Management LLC Has $9.27 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Walleye Capital LLC Has $1.38 Million Stock Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Affinity Asset Advisors LLC Takes $1.25 Million Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Analysts Bullish on Healthcare Stocks: Labcorp Holdings and Abivax SA Sponsored ADR - AInvest
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month High – What’s Next? - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 28.7% in July - Defense World
Abivax Adr (ABVX) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):